| Patricia Mae Schwan, MS, LPC-MH, LMFT, | |
|
14 S Main St Ste 1e, Aberdeen, SD 57401-4189 | |
| (605) 225-1010 | |
| (605) 725-8055 |
| Full Name | Patricia Mae Schwan |
|---|---|
| Gender | Female |
| Speciality | Counselor - Professional |
| Location | 14 S Main St Ste 1e, Aberdeen, South Dakota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679644165 | NPI | - | NPPES |
| 6575370 | Medicaid | SD | |
| 4997373 | Other | SD | WELLMARK |
| 232008 | Other | MIDLANDS CHOICE | |
| 9201555 | Other | SD | DAKOTA CARE |
| Entity Name | Northeastern Mental Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801964952 PECOS PAC ID: 0446155816 Enrollment ID: O20031201000100 |
News Archive
A recent study published in Epilepsia, the official journal of the International League Against Epilepsy (ILAE), indicates that people who have uncontrolled seizures on the left side of their brains are more likely to have learning disabilities, in comparison to people who have seizures on the right side of their brains.
Childhood obesity in the United States is an epidemic - nationwide, 19 percent of children ages 6 to 11 and 17 percent of those 12 to 19 are overweight, according to the Centers for Disease Control and Prevention (CDC). Those who are overweight during childhood also have an increased risk of obesity in adulthood and are at greater risk for complications such as diabetes, high blood pressure and heart disease, because obesity increases total blood volume, which leads to extra stress on the heart.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Bupropion Hydrochloride Extended-Release Tablets USP, (SR), 100 mg, 150 mg and 200 mg, the generic version of GlaxoSmithKline's antidepressant Wellbutrin SR®.
Quanterix Corporation, the single molecule diagnostics company focused on developing and commercializing high sensitivity tests, announced the publication of a breakthrough study of the company's proprietary technology that demonstrates an unprecedented sensitivity for measuring a biomarker for prostate cancer recurrence.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Patricia Mae Schwan, MS, LPC-MH, LMFT, 310 15th Ave Se, Aberdeen, SD 57401-7505 Ph: (605) 226-1304 | Patricia Mae Schwan, MS, LPC-MH, LMFT, 14 S Main St Ste 1e, Aberdeen, SD 57401-4189 Ph: (605) 225-1010 |
News Archive
A recent study published in Epilepsia, the official journal of the International League Against Epilepsy (ILAE), indicates that people who have uncontrolled seizures on the left side of their brains are more likely to have learning disabilities, in comparison to people who have seizures on the right side of their brains.
Childhood obesity in the United States is an epidemic - nationwide, 19 percent of children ages 6 to 11 and 17 percent of those 12 to 19 are overweight, according to the Centers for Disease Control and Prevention (CDC). Those who are overweight during childhood also have an increased risk of obesity in adulthood and are at greater risk for complications such as diabetes, high blood pressure and heart disease, because obesity increases total blood volume, which leads to extra stress on the heart.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Bupropion Hydrochloride Extended-Release Tablets USP, (SR), 100 mg, 150 mg and 200 mg, the generic version of GlaxoSmithKline's antidepressant Wellbutrin SR®.
Quanterix Corporation, the single molecule diagnostics company focused on developing and commercializing high sensitivity tests, announced the publication of a breakthrough study of the company's proprietary technology that demonstrates an unprecedented sensitivity for measuring a biomarker for prostate cancer recurrence.
› Verified 2 days ago
Taylor A Petersen, Counselor Medicare: Not Enrolled in Medicare Practice Location: 14 S Main St Ste 1e, Aberdeen, SD 57401 Phone: 605-225-1010 Fax: 605-725-8055 | |
Madalyn Pederson, Counselor Medicare: Not Enrolled in Medicare Practice Location: 14 S Main St Ste 1e, Aberdeen, SD 57401 Phone: 605-225-1010 | |
Sheila Snover, Counselor Medicare: Not Enrolled in Medicare Practice Location: 628 Circle Dr, Aberdeen, SD 57401 Phone: 605-225-1010 Fax: 605-725-8057 | |
Amy L Hauge, LPC-MH, QMHP Counselor Medicare: Not Enrolled in Medicare Practice Location: 125 Railroad Ave Se Ste 1, Aberdeen, SD 57401 Phone: 605-725-5505 | |
Nancy Yada, Counselor Medicare: Not Enrolled in Medicare Practice Location: 14 S Main St, Suite 1e, Aberdeen, SD 57401 Phone: 605-225-1010 Fax: 605-225-1017 | |
Reagan M Flamboe, Counselor Medicare: Medicare Enrolled Practice Location: 14 S Main St, Suite 1e, Aberdeen, SD 57401 Phone: 605-225-1010 Fax: 605-225-1017 | |
Megan Hulke, Counselor Medicare: Not Enrolled in Medicare Practice Location: 14 S Main St Ste 1e, Aberdeen, SD 57401 Phone: 605-725-4956 Fax: 605-725-8055 |